Cipla has launched CipAir, an innovative AI-driven mobile application designed to facilitate early and convenient asthma screening in India. Clinically validated through a multi-center pan-India study, the tool empowers users to assess their likelihood of asthma, enabling timely medical intervention and management.

Currently available on Android, with an upcoming iOS rollout, CipAir is a free tool integrated into Breathefree, Cipla’s patient support ecosystem for respiratory care. Utilizing advanced acoustic signature analysis and artificial neural network science, the app converts a smartphone into an asthma screening device. By performing three guided exhalations in a quiet environment, users receive personalized results in under a minute, indicating asthma presence, absence, or potential future onset. The app further provides access to lung health resources and expert guidance via the Breathefree platform.

Cipla’s Managing Director & Global CEO, Umang Vohra, emphasized the company’s commitment to leveraging next-gen technology for improving diagnostics, treatment, and patient care. Achin Gupta, CEO, One India Business, highlighted Cipla’s mission to strengthen asthma care in India through innovative solutions like CipAir.

By combining AI technology with patient-centric healthcare, Cipla aims to revolutionize asthma management, ensuring individuals can take charge of their lung health and lead better, healthier lives.